Dotmatics

NEW YORK (GenomeWeb) – This week, Dotmatics launched the Ecosystem Program through which third-party organizations can develop and integrate their scientific applications into its informatics platform.

NEW YORK (GenomeWeb) – Privately-held UK-based informatics solutions provider Dotmatics is planning to expand its business in the North American market and has hired Rusty Irving to head its efforts on that front.

Inform Genomics has tapped Carl de Moor to be its chief technology officer.

Dotmatics has hired Richard Lingard to serve as head of commercial operations. In this role, Lingard will oversee the expansion and running of the company's commercial and customer-facing teams.

Dotmatics said this week that University of Sussex has added Studies Notebook, the company's web-based electronic laboratory notebook, to its existing Dotmatics data management platform.

Dotmatics said this week that AstraZeneca's Neuroscience Innovative Medicines Unit has selected its platform to manage research data associated with its collaborative drug discovery efforts.

Dotmatics said this week that Grunenthal Group, a German pharmaceutical company, has licensed its software to manage and analyze chemical and biological data in its projects.

This week, Dotmatics said that Shanghai Budou Technology will distribute its software products in China.

This week, Dotmatics said that the University of Leeds will use its Vortex software to analyze and visualize data for drug discovery research projects.

Pages

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.